Tasca Therapeutics launches with $52 million in Series A financing co-led by Regeneron Ventures and Cure Ventures, and with participation by Invus Group.
Press Release
Representation of GV Management Company as lead in PeopleOne Health’s $32.3M Series B Financing.
Press Releasse
EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multispecific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales
Press Release
Counsel to Ananda Scientific in collaboration with Yale School of Medicine to conduct investigator initiated clinical trial evaluating Nantheia™ ATL5 for use in treating co-occurring opioid use disorder (OUD) and chronic pain. The study will be led by Principal Investigator Joao P. De Aquino, M.D.
Press Release
Counsel to Novo Nordisk in acquisition of 2seventy’s Hemophilia A program and rights to MegaTAL in vivo gene editing technology.
Press Release
Representation of GV Management Company, as lead, and a16z Bio + in Santa Ana Bio’s $125M Series B Financing. Other investors included TPG, Access Biotechnology, and RTW.
Press Release
NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint subsequently raises $42.5M in an extension to its Series B led by Catalio Capital Management, bringing the total raised to $122.5M. Additional investors in the round include MPM BioImpact, Invus, Sixty Degree Capital, Binney Street Capital, and Arkin Bio-Capital.
Website
The firm counseled TMS Co. Ltd. as it entered strategic collaboration agreements with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING. TMS regained Japan rights to this compound, received a payment of JIXING equity, and obtained Japan rights to JX09. TMS contemporaneously received a private equity investment from RTW
Press Release
Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors
Press Release
Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing
Press Release
Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions
Press Release
Equity investments in multiple portfolio companies, including Hibercell
Website
CRO and Site Agreements for an Open-Label, Phase 2 Study with 30 Sites in 9 Countries exploring the efficiency of Neratinib on Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations Or EGFR Gene Amplification
See Study
Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs
Website
Co-counsel to Vertex on acquisition of ViaCyte, a privately-held biotechnology company that received substantial research funding from the California Institute of Regenerative Medicine
Press Release
